$DRMA
Dermata Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000165495424014274 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $824.3K
YoY Change -9.42%
% of Gross Profit
Research & Development $2.401M
YoY Change 165.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.226M
YoY Change 78.02%
Operating Profit -$3.226M
YoY Change 78.02%
Interest Expense $52.50K
YoY Change -41.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.173M
YoY Change 84.49%
Income Tax
% Of Pretax Income
Net Earnings -$3.173M
YoY Change 84.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.04
COMMON SHARES
Basic Shares Outstanding 2.041M shares 1.316M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.144M
YoY Change -7.33%
Cash & Equivalents $6.144M
Short-Term Investments
Other Short-Term Assets $543.6K
YoY Change -21.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.687M
YoY Change -8.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00
YoY Change -99.88%
TOTAL ASSETS
Total Short-Term Assets $6.687M
Total Long-Term Assets $4.00
Total Assets $6.687M
YoY Change -8.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $863.6K
YoY Change 82.02%
Accrued Expenses $1.083M
YoY Change 146.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.946M
YoY Change 111.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.946M
Total Long-Term Liabilities $0.00
Total Liabilities $1.946M
YoY Change 112.27%
SHAREHOLDERS EQUITY
Retained Earnings -$62.52M
YoY Change 21.99%
Common Stock $168.00
YoY Change -47.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.741M
YoY Change
Total Liabilities & Shareholders Equity $6.687M
YoY Change -8.69%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.173M
YoY Change 84.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.419M
YoY Change 93.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.616M
YoY Change -11638.95%
NET CHANGE
Cash From Operating Activities -3.419M
Cash From Investing Activities
Cash From Financing Activities 4.616M
Net Change In Cash 1.197M
YoY Change -166.11%
FREE CASH FLOW
Cash From Operating Activities -$3.419M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1677768 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
543592 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
540499 usd
CY2024Q3 us-gaap Assets
Assets
6687344 usd
CY2023Q4 us-gaap Assets
Assets
7978634 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
863595 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
866028 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1082521 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
757588 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1946116 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1623616 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
168 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
26 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67265462 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59742870 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62524402 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53387878 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
4741228 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6687344 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7978634 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001853816
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
261998 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1677768 shares
drma Incremental Fair Value Of March2023 Warrant Modification
IncrementalFairValueOfMarch2023WarrantModification
144765 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40739
dei Entity Registrant Name
EntityRegistrantName
DERMATA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3218736
dei Entity Address Address Line1
EntityAddressAddressLine1
3525 Del Mar Heights Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
#322
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
800-2543
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2040768 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6143752 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
261998 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2401359 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
902977 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6011201 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2934541 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
824294 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
909001 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3301753 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2887533 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3225653 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1811978 usd
us-gaap Operating Expenses
OperatingExpenses
9312954 usd
us-gaap Operating Expenses
OperatingExpenses
5822074 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3225653 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1811978 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9312954 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5822074 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
52497 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
92767 usd
us-gaap Interest Income Other
InterestIncomeOther
176431 usd
us-gaap Interest Income Other
InterestIncomeOther
161357 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3173156 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719211 usd
us-gaap Net Income Loss
NetIncomeLoss
-9136523 usd
us-gaap Net Income Loss
NetIncomeLoss
-5660717 usd
CY2024Q3 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-2.04
CY2023Q3 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-8.09
drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-10.22
drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-36.91
CY2024Q3 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
1554680 shares
CY2023Q3 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
212544 shares
drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
894168 shares
drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
153380 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587234 usd
CY2024Q1 drma Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3134262 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3807990 usd
CY2024Q2 drma Issuance Of Common Stock Upon Exercise Of Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockUponExerciseOfWarrantsNetOfIssuanceCostsAmount
2320463 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19608 usd
CY2024Q2 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-828 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2829106 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3318127 usd
CY2024Q3 drma Issuance Of Pre Funded Warrants And Warrants Net Of Issuance Costs
IssuanceOfPreFundedWarrantsAndWarrantsNetOfIssuanceCosts
3093038 usd
CY2024Q3 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
168 usd
CY2024Q3 drma Issuance Of Common Stock From Atm Sales Net Of Issuance
IssuanceOfCommonStockFromAtmSalesNetOfIssuance
1482059 usd
CY2024Q3 drma Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
0 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20992 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3173156 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
4741228 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131260 usd
CY2023Q1 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4174985 usd
CY2023Q1 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
153 usd
CY2023Q1 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-40 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8088070 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
1512102 usd
CY2023Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
34 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8030019 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q3 drma Issuance Costs
IssuanceCosts
-35419 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719211 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6406566 usd
us-gaap Profit Loss
ProfitLoss
-9136523 usd
us-gaap Profit Loss
ProfitLoss
-5660717 usd
us-gaap Share Based Compensation
ShareBasedCompensation
627834 usd
us-gaap Share Based Compensation
ShareBasedCompensation
393614 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3095 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11294 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10324 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-22244 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
272774 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16427 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
887189 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
399091 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8249334 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5261626 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6955611 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5651668 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
168 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
187 usd
drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
-828 usd
drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
-40 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6954951 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5651815 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1294383 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
390189 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6241294 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6143752 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6631483 usd
drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
-45 usd
drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
0 usd
drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
1526232 usd
drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
0 usd
drma Equity Issuance Costs In Accounts Payable Or Accrued Expenses
EquityIssuanceCostsInAccountsPayableOrAccruedExpenses
60051 usd
drma Equity Issuance Costs In Accounts Payable Or Accrued Expenses
EquityIssuanceCostsInAccountsPayableOrAccruedExpenses
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
950 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
950 usd
CY2024Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
6100000 usd
CY2024Q3 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
-62500000 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
8200000 usd
CY2023 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
6400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company is exposed to credit risk in the event of a default by the financial institutions holding the Company’s cash and cash equivalents to the extent of the amounts held in excess of FDIC limits. The Company limits its credit risk by placing its cash and cash equivalents with financial institutions it believes are of high quality. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5121064 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
316312 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
42.30
drma Description Of Abeyance Shares
DescriptionOfAbeyanceShares
the Holder left 182,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request, which were then delivered to the Holder on January 8, 2024
CY2023Q4 drma Temporary Equity Shares Abeyance
TemporaryEquitySharesAbeyance
182000 shares
CY2023Q2 drma Proceeds Cash From Pipe
ProceedsCashFromPipe
1500000 usd
CY2023Q2 drma Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
300000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5068723 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
772973 shares
CY2024Q2 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
5.16
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.91
CY2023Q4 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
5.16
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.7655
CY2023Q4 drma Received Net Cash Proceeds
ReceivedNetCashProceeds
2000000.0 usd
CY2023Q4 drma Offering Expenses
OfferingExpenses
3000000.0 usd
drma Warrant Reduced Description
WarrantReducedDescription
from $318.00 to $42.30 per share upon closing of the March 2023 Offering. The original expiration date of the April 2022 PIPE Common Warrants was May 12, 2027, which was extended to five years after the closing of the March 2023
CY2024Q1 drma Description Of Stock Option Cancellation
DescriptionOfStockOptionCancellation
in accordance with an option cancellation agreement. Accordingly, 6,747 of the 6,763 stock options outstanding as of December 31, 2023, were cancelled in February 2024
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
568372 usd
CY2024Q3 drma Common Stock Par Or Stated Values Per Share
CommonStockParOrStatedValuesPerShare
1.64
us-gaap Contractually Specified Servicing Fees Amount
ContractuallySpecifiedServicingFeesAmount
7000000.0 usd
us-gaap Other Expenses
OtherExpenses
4700000 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
363000 shares
drma Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
1382000 shares

Files In Submission

Name View Source Status
0001654954-24-014274-index-headers.html Edgar Link pending
0001654954-24-014274-index.html Edgar Link pending
0001654954-24-014274.txt Edgar Link pending
0001654954-24-014274-xbrl.zip Edgar Link pending
drma-20240930.xsd Edgar Link pending
drma_10q.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drma-20240930_lab.xml Edgar Link unprocessable
drma-20240930_cal.xml Edgar Link unprocessable
drma-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drma_10q_htm.xml Edgar Link completed
drma-20240930_def.xml Edgar Link unprocessable